A meta-analysis of five RCTs shows baxdrostat significantly reduces SBP and DBP in resistant hypertension via selective aldosterone synthase inhibition, sparing cortisol, supporting its role as a promising novel therapeutic option.
Abstract
Background:
Resistant hypertension (RH), defined as persistently elevated blood pressure despite treatment with three or more antihypertensive agents including a diuretic, affects a substantial proportion of hypertensive patients and is associated with high cardiovascular morbidity and mortality. Excess aldosterone activity is a key pathophysiologic driver. Baxdrostat, a highly selective aldosterone synthase inhibitor, suppresses aldosterone production while sparing cortisol, providing a targeted mechanism for RH management. A comprehensive synthesis of randomized evidence, incorporating recent 2026 trial data, has been lacking.
Methods:
This systematic review and meta-analysis followed a preregistered PROSPERO protocol (CRD420251038564) and PRISMA 2020 guidelines. PubMed, Embase, Cochrane CENTRAL, and Scopus were searched through December 2025 for randomized controlled trials (RCTs) comparing baxdrostat to placebo in adults with RH. Co-primary efficacy endpoints were changes in systolic (SBP) and diastolic blood pressure (DBP) from baseline. The primary safety outcome was hyperkalemia (serum potassium ≥5.5 mmol/L). Random-effects models were used for pooling. Risk of bias was assessed using Cochrane RoB 2, and evidence certainty was evaluated with GRADE.
Results:
Five RCTs (BrigHTN, HALO, BaxHTN, Bax24, and Dwyer et al.) totaling
1,996 patients
were included. Baxdrostat significantly reduced SBP (mean difference [MD]
–6.98 mmHg
; 95% CI –9.78 to –4.18; I
2
=93%; P<0.00001) and DBP (MD
–3.58 mmHg
; 95% CI –4.40 to –2.75; I
2
=51%; P<0.00001). Hyperkalemia risk was increased (risk ratio [RR]
3.77
; 95% CI 2.29-6.21; I
2
=0%; P<0.00001; 103 events with baxdrostat vs. 19 with placebo). Most hyperkalemia cases were mild-to-moderate and manageable. No significant differences occurred in overall or serious adverse events.
Conclusions:
This meta-analysis of five RCTs (N=1,996) shows baxdrostat significantly reduces SBP and DBP in resistant hypertension via selective aldosterone synthase inhibition, sparing cortisol. Hyperkalemia risk is elevated but manageable, supporting its role as a promising novel therapeutic option.
Background:
Aldosterone dysregulation is becoming more widely acknowledged as a key factor in resistant hypertension. Baxdrostat, a highly selective aldosterone synthase inhibitor that shows a 100:1 preference for CYP11B2 over CYP11B1, has been tested in various randomized controlled trials involving different hyper...
Adir Alper, M. Lerner, A. Karthikeyan et al.· Circulation· 0 citations
Baxdrostat was effective in lowering systolic blood pressure, but increased the risk of hyperkalemia, which supports it as an alternative therapy for uncontrolled and resistant hypertension, with cautious use in patients at risk for hyperkalemia.
A. Bortolotto, P. Goncalves, L. Bortolotto· European Heart Journal· 0 citations
Introduction:
Resistant hypertension remains difficult to control and is associated with increased cardiovascular and renal risk. Baxdrostat, a selective aldosterone synthase inhibitor, has emerged as a potential therapeutic option for adults with uncontrolled or resistant hypertension. We evaluated the efficacy and...
A. Gadelmawla, A. Hageen, R. Rateb et al.· Circulation· 0 citations
Background:
Hypertension is one of the primary contributors to the global burden of non-communicable diseases. Individuals who maintain blood pressure levels above the target range, despite being on maximally tolerated doses of three or more different classes of antihypertensive drugs, are classified as treatment-re...
S. V. Z. Rizvi, Kanza Farhan, M. O. Larik et al.· Circulation· 0 citations
Background:
Resistant and uncontrolled hypertension carries high cardiovascular and renal risk, with aldosterone excess as a central driver. Baxdrostat, a highly selective aldosterone synthase (CYP11B2) inhibitor, was recently approved, yet prior syntheses pooled only a subset of trials or combined agents. We provid...
K. Warraich, Muhammad Mujtaba Rasool, M. Murtaza et al.· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.